Showing: 1 - 10 of 81 RESULTS

Taysha Gene Therapies Receives Rare Pediatric Disease Designation and Orphan Drug Designation for TSHA-102 as a Treatment for Rett Syndrome

Program leverages novel miRARE platform technology used to control transgene expression on a cellular basis

TSHA-102 anticipated to submit Investigational New Drug application in 2021

Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced that it has received rare pediatric disease designation and orphan drug designation from the U.S. Food and Drug Administration (FDA) for TSHA-102, an AAV9-based gene therapy in development for the treatment of Rett syndrome. Taysha anticipates that it will submit an Investigational New Drug (IND) application for TSHA-102 to the FDA in 2021.

Rett syndrome is one of the most common genetic causes of severe intellectual disability worldwide, with a prevalence of over 25,000 cases in the U.S. and European Union (EU). It is an X-linked disease that primarily occurs in females, but it can be seen very rarely in males. It is usually recognized in children between six to 18 months of age as they begin to miss developmental milestones or lose abilities they had developed. Individuals with Rett syndrome also show symptoms that include loss of speech, loss of purposeful use of hands, loss of mobility, seizures, cardiac impairments, breathing issues and sleep disturbances.

“Patients with Rett syndrome are currently managed with symptomatic treatments as there are no therapies approved to treat the underlying cause of disease,” said Berge Minassian, M.D., Chief Medical Advisor of Taysha and Chief of Pediatric Neurology at the University of Texas Southwestern Medical Center (UT Southwestern). Dr. Minassian is credited with describing the CNS isoform of the MECP2 gene which is responsible for neuronal and synaptic function throughout the brain. “Gene therapy offers a potentially curative option for patients suffering with Rett syndrome.”

Rett syndrome is caused by mutations in the MECP2 gene. TSHA-102 is designed to deliver a healthy version of the MECP2 gene as well as the miRNA-Responsive Auto-Regulatory Element, miRARE, platform technology to control the level of MECP2 expression. “TSHA-102 represents an important step forward in the field of gene therapy, where we are leveraging a novel regulatory platform called miRARE to prevent the overexpression of MECP2,” said Steven Gray, Ph.D., Chief Scientific Advisor of Taysha and Associate Professor in the Department of Pediatrics at UT Southwestern. “In collaboration with Sarah Sinnett, Ph.D. to develop miRARE, our goal was to design a regulated construct that allowed us to control MECP2 expression to potentially avoid adverse events that are typically seen with unregulated gene therapies.”

The FDA defines a rare pediatric disease as a serious or life-threatening disease in which the disease manifestations primarily affect individuals aged from birth to 18 years. Pediatric diseases recognized as “rare” affect under 200,000 people in the U.S. The Rare Pediatric Disease Priority Review Voucher Program is intended to address the challenges that drug companies face when developing treatments for these unique patient populations. Under this program, companies are

U.S. pauses Eli Lilly’s trial of a coronavirus antibody treatment over safety concerns

  • Eli Lilly’s phase-three trial of its ACTIV-3 monoclonal antibody treatment for coronavirus has been paused due to potential safety concerns.
  • The ACTIV-3 trial is designed to test a monoclonal antibody developed by Eli Lilly in combination with remdesivir, an anti-viral with emergency use authorization for the virus.
  • It’s one of several ongoing trials, as part of the National Institute of Health’s “Activ” program, designed to accelerate the development of vaccine treatments in partnership with the pharmaceutical industry.



a group of people standing around a plane: In this May 2020 photo provided by Eli Lilly, researchers prepare mammalian cells to produce possible COVID-19 antibodies for testing in a laboratory in Indianapolis.


© Provided by CNBC
In this May 2020 photo provided by Eli Lilly, researchers prepare mammalian cells to produce possible COVID-19 antibodies for testing in a laboratory in Indianapolis.

Eli Lilly’s late-stage trial of its leading monoclonal antibody treatment for the coronavirus has been paused by U.S. health regulators over potential safety concerns, the company confirmed to CNBC on Tuesday.

Loading...

Load Error

“Safety is of the utmost importance to Lilly. We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment,” a spokeswoman Molly McCully told CNBC. “Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study.”

The company’s shares fell by about 3% in afternoon trading after the news started to leak out over Twitter.

The news comes less than 24 hours after Johnson & Johnson confirmed that its late-stage coronavirus vaccine trial was paused after a participant reported an “adverse event” the day before.

Dr. Mathai Mammen, global head of Janssen research and development at J&J, told investors on a conference call Tuesday that the company still has “very little information” on the reason for the holdup, including if the patient received the vaccine or the placebo. Preliminary information has been sent to the data safety monitoring board for review, he added.

Medical experts note that pauses in large clinical trials are not uncommon. They added it’s possible the bad reaction could be result of an unrelated illness, and not the drug itself. The review from the data and safety monitoring board will help determine that.

The ACTIV-3 trial is designed to test a monoclonal antibody developed by Eli Lilly in combination with Gilead Sciences’ remdesivir, an anti-viral with emergency use authorization for the virus. It’s one of several ongoing trials that are part of the National Institute of Health’s “Activ” program, which is designed to accelerate the development of Covid-19 vaccines and treatments. It is also backed by Operation Warp Speed, the Trump administration’s effort to manufacturer and distribute vaccines to fight Covid-19.

Eli Lilly’s drug is part of a class of treatments known as monoclonal antibodies, which are made to act as immune cells that scientists hope can fight the virus. The treatment was developed using a blood sample from one of the first U.S. patients who recovered from Covid-19. AstraZeneca and Regeneron, among other companies, are also working on so-called antibody treatments.

Monoclonal antibody treatments hit the headlines this month after news broke

Ionis’ inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis | News

CARLSBAD, Calif., Oct. 13, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that data from a clinical trial of IONIS-ENAC-2.5Rx demonstrated a significant decrease in the expression of epithelial sodium channel (ENaC) in subjects with cystic fibrosis (CF). The study showed a mean 55.6 percent decrease (p<0.05) in ENaC mRNA expression at the 75 mg dose in the multidose segment of the trial. The study represents the first time an antisense medicine delivered directly to the lung via a nebulizer has shown a significant reduction in ENaC messenger RNA levels. In preclinical studies, ENaC mRNA reductions of 40 percent or more resulted in significant improvement in mouse models of CF lung disease.

IONIS-ENAC-2.5Rx is an investigational antisense medicine designed to reduce the expression of ENaC in the lung. ENaC is believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene. Data from the Phase 1 study will be presented via e-poster at the 2020 North American Cystic Fibrosis Conference, which will hold virtual sessions and discussions Oct. 21-23.

Cystic fibrosis is a life-threatening disease affecting approximately 30,000 people in the U.S. and about 70,000 worldwide. Although CF is a multisystem disease, the main cause of morbidity and mortality is lung disease, characterized by small airway obstruction due to mucus accumulation, decreased mucus clearing and subsequent inflammation, infections and lung function decline.

“We are very encouraged by these data, which demonstrate attractive tolerability and safety for IONIS-ENAC-2.5Rx with substantial target reduction and the convenience of once weekly administration. The data also confirm our expectations for aerosol delivery of antisense medicines for lung diseases based on a wealth of preclinical data,” said Brett P. Monia, Ph.D., Ionis’ chief executive officer. “These results point to the exciting potential for aerosol delivery of other Ionis medicines that we plan to advance to the clinic, including treatments for chronic obstructive pulmonary disease, or COPD, and severe asthma.”

The company also plans to initiate a clinical study to evaluate IONIS-ENAC-2.5Rx in patients with COPD associated with chronic bronchitis starting later this year. IONIS-ENAC-2.5Rx is one of more than 20 potentially transformative antisense medicines in the growing Ionis-owned pipeline that the company is prioritizing and preparing for commercialization.

The primary endpoint of the study was evaluation of safety and pharmacokinetics of IONIS-ENAC-2.5Rx delivered via a Pari eFlow mesh nebulizer. In the single escalating dose study, 32 subjects in four cohorts received a single dose of 3, 10, 37.5, or 100 mg and were followed for 30 days. In the multiple ascending dose study, 24 subjects in three cohorts received four doses of 10, 37.5, or 75 mg once weekly, with an additional dose administered during the first week. An additional cohort of eight subjects received a 37.5 mg dose given thrice weekly for 10 doses. Subjects were followed for 13 weeks after dosing. Fiberoptic bronchoscopy including bronchial brushings and bronchoalveolar lavage was

Ionis’ inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis

CARLSBAD, Calif., Oct. 13, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that data from a clinical trial of IONIS-ENAC-2.5Rx demonstrated a significant decrease in the expression of epithelial sodium channel (ENaC) in subjects with cystic fibrosis (CF). The study showed a mean 55.6 percent decrease (p

(PRNewsfoto/Ionis Pharmaceuticals, Inc.)

IONIS-ENAC-2.5Rx is an investigational antisense medicine designed to reduce the expression of ENaC in the lung. ENaC is believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene. Data from the Phase 1 study will be presented via e-poster at the 2020 North American Cystic Fibrosis Conference, which will hold virtual sessions and discussions Oct. 21-23.

Cystic fibrosis is a life-threatening disease affecting approximately 30,000 people in the U.S. and about 70,000 worldwide. Although CF is a multisystem disease, the main cause of morbidity and mortality is lung disease, characterized by small airway obstruction due to mucus accumulation, decreased mucus clearing and subsequent inflammation, infections and lung function decline.

“We are very encouraged by these data, which demonstrate attractive tolerability and safety for IONIS-ENAC-2.5Rx with substantial target reduction and the convenience of once weekly administration. The data also confirm our expectations for aerosol delivery of antisense medicines for lung diseases based on a wealth of preclinical data,” said Brett P. Monia, Ph.D., Ionis’ chief executive officer. “These results point to the exciting potential for aerosol delivery of other Ionis medicines that we plan to advance to the clinic, including treatments for chronic obstructive pulmonary disease, or COPD, and severe asthma.”

The company also plans to initiate a clinical study to evaluate IONIS-ENAC-2.5Rx in patients with COPD associated with chronic bronchitis starting later this year. IONIS-ENAC-2.5Rx is one of more than 20 potentially transformative antisense medicines in the growing Ionis-owned pipeline that the company is prioritizing and preparing for commercialization.

The primary endpoint of the study was evaluation of safety and pharmacokinetics of IONIS-ENAC-2.5Rx delivered via a Pari eFlow mesh nebulizer. In the single escalating dose study, 32 subjects in four cohorts received a single dose of 3, 10, 37.5, or 100 mg and were followed for 30 days. In the multiple ascending dose study, 24 subjects in three cohorts received four doses of 10, 37.5, or 75 mg once weekly, with an additional dose administered during the first week. An additional cohort of eight subjects received a 37.5 mg dose given thrice weekly for 10 doses. Subjects were followed for 13 weeks after dosing. Fiberoptic bronchoscopy including bronchial brushings and bronchoalveolar lavage was performed during screening and after completion of dosing in the MAD cohorts. Quantitative RT-PCR was performed from the bronchial cell brushings to evaluate ENaC mRNA levels.

About Ionis Pharmaceuticals

As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our

Takeda Group Begins Manufacturing COVID-19 Plasma Treatment Ahead of Approval | Top News

NEW YORK (Reuters) – The Takeda Pharmaceutical Co-led group that is developing a blood plasma treatment for COVID-19 has started manufacturing while the late-stage trial to determine whether it works is ongoing, Takeda Chief Executive Christophe Weber said on Monday.

The group, known as the CoVIg Plasma Alliance, enrolled its first patient in the Phase III trial on Friday after months of delays. It aims to enroll 500 adult patients from the United States, Mexico and 16 other countries and hope to have results by the end of the year.

“The likelihood it works is very high,” Weber said in an interview. “And that’s why we have launched a campaign in order to accelerate the donation of convalescent plasma to manufacture and produce this product.”

The alliance, which includes CSL Behring, Germany’s Biotest AG and other companies, is testing a hyperimmune globulin therapy, which is derived from blood plasma of people who have recovered from COVID-19. Hyperimmune globulin therapy offers a standardized dose of antibodies and does not need to be limited to patients with matching blood types.

That makes it more advanced and convenient than treatment with convalescent plasma drawn from recovered patients.

The manufacturing process is expensive.

Weber said the treatment could be slightly more costly to make than monoclonal antibody treatments like the ones Regeneron Pharmaceuticals Inc and Eli Lilly and Co have developed. The alliance does not intend to profit from the treatment, Weber said.

The Takeda CEO said he does not know how many doses of the treatment the group will be able to produce by the end of the year. That will depend on donations as well as the dosage size they decide to test in the clinical trial.

The trial will test the hyperimmune globulin therapy in combination with Gilead Sciences Inc’s antiviral drug remdesivir compared with patients who get remdesivir alone, he said.

(Reporting by Michael Erman; Editing by Bill Berkrot)

Copyright 2020 Thomson Reuters.

Source Article

DNA Dental Comprises the Best Dentist in Dallas, TX, Offering Cosmetic, General, and Restorative Dental Care and Treatment Solutions – Press Release

DNA Dental Comprises the Best Dentist in Dallas, TX, Offering Cosmetic, General, and Restorative Dental Care and Treatment Solutions

Dallas, TX – Dallas, TX residents who are in search of 5-star and premium dental care and treatment solutions can now rest assured that the team at DNA Dental brings this quality of services to them at affordable rates. The dental clinic in Dallas, TX boasts a team of experienced and professional dental specialists who are constantly improving on their dental practice to ensure that each patient is given the attention and care they deserve.

Focused on improving the oral health and wellness of the members of the community, DNA Dental has proudly expanded on its dentistry practice to offer a wide range of dental solutions, including the very best children’s dentistry solutions in the area. Children who come into the dental clinic will have access to the very best and experienced pediatric dentists who are committed to creating the best dental care and treatment experiences using the latest dental tools, technology, and procedures while also aiming for a pain-free dental care and treatment experience.

The entire team of Dentist at DNA Dental also focus on helping children to form the right dental foundations for their oral health and wellness needs. Added to this, the dental clinic boasts of the best Cosmetic Dentist in the Dallas, TX area. The professional cosmetic dentist offers a range of popular cosmetic dental services that are designed to help patients to reach the goal they have for a bright and beautiful smile.

Describing the dental solutions offered at the clinic, Dr. Darya Timin, the spokesperson for DNA Dental said, “Here at DNA Dental, we are committed to providing gentle care to every member of your family. We understand that you may feel nervous about your dental visits, and we are here to help you feel relaxed and comfortable. Our dentists and team are proud to provide quality, gentle dentistry solutions. We invite you to contact our friendly team today to learn more about our comprehensive services and to schedule your next appointment with one of our experienced dentists. Take your next step toward a healthy smile today!”

Serving patients in Dallas, TX, and the surrounding areas, DNA Dental also offers comprehensive restorative dentistry solutions including dental bridges, dental crowns, dental implants, dentures, and dental fillings.

Patients who visit the clinic will have access to the latest dental technologies, as well as a cutting-edge approach to dental care and treatment.

DNA Dental is located at 6162 E Mockingbird Ln Ste 205, Dallas, TX 75214, US. For top-quality dental care and treatment solutions, contact their team by calling +1 214-817-3113 to schedule an appointment. For additional information regarding their services, send an email to [email protected] or visit the dental clinic’s website.

Media Contact
Company Name: DNA Dental
Contact Person: Dr. Darya Timin
Email: Send Email
Phone: +1 214-817-3113
Address:6162 E Mockingbird Ln Ste 205
City: Dallas
State: TX
Country: United States
Website: https://dnadentaldallas.com/

// Load the SDK Asynchronously (function(d){ var js, id …

Bill Gates says Trump’s coronavirus treatment won’t work for everyone, shouldn’t be called ‘cure’

Microsoft co-founder and billionaire philanthropist Bill Gates said Sunday that the Regeneron antibody cocktail administered to President Trump to treat a case of COVID-19 shouldn’t be referred to as a “cure.”

“The word ‘cure’ is inappropriate because it doesn’t work for everyone,” Gates told NBC’s “Meet the Press.” “But yes, of all the therapeutics, this is the most promising.”

Although an effective vaccine is an ultimate goal for putting an end to the pandemic, Gates noted that monoclonal antibodies allow for treatment that doesn’t require admission to a high percentage of the population.

“With the monoclonal antibodies, it’s only once somebody tests positive, show symptoms and they’re old enough they’re at risk,” Gates said. “That’s the target for this therapeutic.”

He added that if the monoclonal antibody treatments can be approved for an emergency use authorization in a timely manner, they will “save more lives than the vaccine will,” particularly if given in low doses.

“The president got eight grams and we’re trialing things that are down at more like 0.7 grams, and 0.3 grams,” Gates said. “Of course, that changes the cost and capacity a lot but that’s also unproven at this point, but it’s important that we explore.”

REGENERON CEO SAYS PRESIDENT TRUMP’S ANTIBODY COCKTAIL TREATMENT IS ‘CASE REPORT’

Gates is optimistic that antibody treatments, including those developed by Regeneron and Eli Lilly, could potentially earn an emergency use authorization within the next few months, but warned against the president’s recent push for the regulators to accelerate the approval timeline. 

“You don’t want politicians saying something should be approved because it’s wrong to think of political pressure as needing to be appropriate in these cases,” he said.

Ticker Security Last Change Change %
REGN REGENERON PHARMACEUTICALS INC. 602.07 +2.19 +0.37%
LLY ELI LILLY & COMPANY 156.88 +3.38 +2.20%

As for vaccines, Gates said the majority of vaccines will likely get emergency use authorizations by early next year, with Pfizer and BioNTech’s vaccine potentially being an exception with a possible authorization by the end of this year.

“The phase three data is the key thing, particularly for the safety, making sure we’re not seeing side effects. So the tool is ramping up and, over the course of the first half of the year, those volumes will get to the point where we really will be asking Americans to, you know, step forward,” Gates said. “The effectiveness could range, you know, could be as low as 50% or as high as 80 [percent] or 90% and, different of the vaccines, some will fail completely and others will hit a very high bar. But we don’t know yet.”

Ticker Security Last Change Change %
PFE PFIZER INC. 36.79 -0.10 -0.27%
BNTX BIONTECH 89.04 +1.09 +1.24%
JNJ JOHNSON & JOHNSON 150.97 +2.08 +1.40%
MRNA MODERNA INC. 73.00 +0.07 +0.10%
AZN ASTRAZENECA PLC 54.72 +0.63 +1.16%

He added that almost all of the vaccines will

Eric Trump falsely calls president’s coronavirus treatment a vaccine

President Trump’s son Eric on Sunday called his father’s treatment for COVID-19 a vaccine that he further claimed the president helped create from “day one.”



Donald Trump wearing a suit and tie talking on a cell phone: Eric Trump falsely calls president's coronavirus treatment a vaccine


© Getty Images
Eric Trump falsely calls president’s coronavirus treatment a vaccine

“My father literally started day one creating this vaccine. He worked to push this vaccine and now my father just took it and you see how well he got over it,” Eric Trump told ABC “This Week’s” Jon Karl.

“Wait, wait,” Karl interrupted before Eric Trump said that Americans should be inspired and proud by what doctor’s call his father’s speedy recovery from an illness that has killed more than 214,000 and infected 7.7 million people in the U.S. alone.

“Can you clarify that you said your father just took a vaccine?” Karl asked.

“Meaning when he was at Walter Reed. The medicines that he was taking,” Eric Trump answered, before adding that until his father went to the hospital, “he felt horrible.”

President Trump’s doctors said that he was given a steroid in response to low oxygen levels, the antiviral drug Remdesivir and an experimental antibody therapy from Regeneron.

There is no approved or authorized vaccine for COVID-19 in the U.S. or in the world. Several companies and research teams globally are in a multi-billion dollar race to develop a vaccine, hoping that one might be delivered by early 2021.

President Trump was taken to Walter Reed National Military Medical Center on Oct. 2 after announcing early that morning that he and first lady Melania Trump had tested positive for coronavirus. His doctors eventually admitted that the president was given oxygen at the White House before he was taken on Marine One to the hospital.

Eric Trump said on Sunday by the very next day his father sounded “tremendous,” the same day doctors said the president once again had to be given oxygen at Walter Reed.

“I spoke to him three times that next Saturday. The guy sounded 100 percent. It was amazing,” Eric Trump said.

Doctors and White House staff sent a series of conflicting messages on the president’s health throughout that weekend. The president was also criticized for leaving his hospital room that Sunday for a drive to wave to supporters while he was infected with the highly contagious virus.

On Monday, President Trump was discharged from the hospital, returning to the White House that evening where he walked up the South Portico stairs to the Truman Balcony and took off his mask before walking inside the residence where some of his staff could be seen.

Eric Trump on Sunday lauded his father’s personal efforts in pushing for a vaccine, without acknowledging that doctors never said his father took a vaccine, and instead was offered a cocktail of experimental therapeutics.

“It actually probably goes to speak to how good some of these vaccines are that are being created,” Eric Trump told ABC. “What my father’s done on the vaccine front no one could have done. No one could have

Bill Gates on Trump virus treatment: The word ‘cure’ is inappropriate because it won’t work for everyone

Microsoft founder and philanthropist Bill Gates said Sunday that the monoclonal antibodies treatment President TrumpDonald John TrumpNorth Korea unveils large intercontinental ballistic missile at military parade Trump no longer considered a risk to transmit COVID-19, doctor says New ad from Trump campaign features Fauci MORE received for his coronavirus infection is not a “cure,” but is the most promising option thus far.

“The word ‘cure’ is inappropriate because it won’t work for everyone,” Gates said Sunday on NBC’s “Meet the Press.” “But of all the therapeutics, this is the most promising.”

Gates added that the Bill & Melinda Gates Foundation has “been working with companies doing antibodies, we reserved factory capacity back in the spring, and now we’re partnered with Eli Lilly, who with Regeneron, has been the fastest to get these antibodies ready.”

“They could reduce the death rate quite a bit … adding this to the tools would be a great thing,” he added.

“They call them therapeutic, but to me it wasn’t therapeutic,” Trump said in a video he tweeted last week, five days after receiving the experimental treatment from the biotech company Regeneron

Trump said that he felt better immediately after taking the drugs.

“I call that a cure,” he said. “It’s a cure.”

Bill Gates on Sunday also warned against politicians opening large venues without social-distancing measures.

“I guess politicians will show what their value system is there,” he said. “Society should be able to have things like schooling that get a priority, vs. certain more entertainment-related things.”

“The only way we’ll get completely back to normal is by having … a vaccine that is super effective and that a lot of the people take,” he said.

Gates went on to express confidence that ” it’s likely that by early next year that several of these vaccines” currently in development “will get that emergency-use authorization.”

Source Article

Chris Christie released from hospital after receiving treatment for COVID-19

Chris Christie was released from a New Jersey hospital on Saturday, a week after he was admitted following a positive COVID-19 test. Christie, who made the announcement on Twitter, has been quiet on social media since he began treatment last weekend.

“I am happy to let you know that this morning I was released from Morristown Medical Center,” Christie tweeted Saturday. “I want to thank the extraordinary doctors & nurses who cared for me for the last week. Thanks to my family & friends for their prayers. I will have more to say about all of this next week.”

The former New Jersey Governor is one of several people in Trump’s orbit to test positive for COVID-19 after attending a Rose Garden event on September 26 where the president announced the nomination of Supreme Court nominee Amy Coney Barrett. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has since described it as a “super spreader” event.

“We had a super-spreader event in the White House and it was in a situation where people were crowded together and were not wearing masks. So the data speak for themselves,” Fauci said. 

Christie also notably helped Mr. Trump with debate preparation, spending hours with him over several days leading up to the first presidential debate, which was held a few days before Christie and Mr. Trump announced they tested positive for the virus. 

Christie was admitted to the hospital hours after announcing he had tested positive for COVID-19. 

“I just received word that I am positive for COVID-19,” Christie tweeted last Saturday, October. 3. “I want to thank all of my friends and colleagues who have reached out to ask how I was feeling in the last day or two. I will be receiving medical attention today and will keep the necessary folks apprised of my condition.”

“While I am feeling good and only have mild symptoms, due to my history of asthma we decided this is an important precautionary measure,” Christie wrote. “I am thankful for our hardworking medical professionals and look forward to coming home soon.”

According to the White House, President Trump tested positive for COVID-19 on Thursday, October 1. He was admitted to Walter Reed Medical Center the next day, and released back to the White House four days later. 

President Trump is scheduled to hold his first public event since testing positive on Saturday. He plans to speak from the South Lawn balcony about “law and order,” in what the White House is calling a “peaceful protest” expected to draw hundreds of people.

The medications used in the president’s treatment plan